Baxter International Inc (BAX) 46.85 $BAX
Next Resistance Level for Baxter International (BAX) is $47.00
Comtex SmarTrend(R) - Mon Jul 11, 8:44AM CDT
Shares of Baxter International (NYSE:BAX) have bullishly opened above the pivot of $46.50 today and have reached the first resistance level of $46.82. Investors may be interested in a cross of the next upside pivot targets of $47.00 and $47.50.
BAX: 46.85 (+0.36)
Baxter International: Health Canada Okays AMIA APD System
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 7:27AM CDT
Baxter International Inc. (BAX) is forging ahead with its expansion plans in Canada with the launch of AMIA Automated Peritoneal Dialysis (APD) System.
BSX: 23.64 (-0.13), ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), NUVA: 61.00 (-0.57)
Baxter Recognized as One of the Most Community-Minded Companies in the United States by Points of Light
BusinessWire - Tue Jun 28, 2:00PM CDT
Baxter International Inc. was recognized for the third consecutive year as one of the most community-minded companies in the nation, as a part of the Civic 50. Civic 50 is an initiative of Points of Light - the world's largest organization dedicated to volunteer service, mobilizes millions of people to take action and change the world. Points of Light sets the standard for corporate civic engagement and creates a roadmap for companies seeking to best use their time, talent, and resources to improve the quality of life in the communities where they do business.
BAX: 46.85 (+0.36)
ResMed : All Eyes on Brightree Buyout , Growth Plans on Track
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 9:11AM CDT
ResMed's partnership with Brightree will expand its Air solutions platform thus increasing its end-to-end value proposition by boosting its SDB products.
ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), ENZY: 8.54 (-0.08), RMD: 64.02 (-0.26)
Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 8:30AM CDT
Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
BLK: 357.37 (+9.87), BAX: 46.85 (+0.36), IVZ: 26.86 (+1.04), FLR: 53.19 (+1.15), LM: 31.26 (+1.02)
Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 23.64 (-0.13), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), GHDX: 27.90 (-0.01)
FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 115.22 (-0.52), MDT: 88.92 (+0.41), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56)
Bull of the Day: Baxter International (BAX)
Jeremy Mullin - Zacks Investment Research - Fri Jun 24, 6:00AM CDT
Bull of the Day: Baxter International (BAX)
BAX: 46.85 (+0.36)
GNC Gains as Buyout Rumors of Vitamin Shoppe Resurface
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:32AM CDT
The Vitamin Shoppe buyout rumor first buzzed in immediately after GNC Holdings Inc.'s (GNC) earnings call in the last quarter.
BSX: 23.64 (-0.13), HLF: 61.87 (+0.89), BAX: 46.85 (+0.36), GNC: 26.34 (+0.59)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), HOLX: 35.71 (+0.10)
Stryker (SYK) Hits 52-Week High on Positive FY16 View
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:14AM CDT
Share price of Stryker Corp (SYK) rallied to a new 52-week high of $116.99 on Jun 20.
MASI: 52.52 (+0.07), BAX: 46.85 (+0.36), CRY: 12.20 (+0.01), SYK: 122.82 (+0.17)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 23.64 (-0.13), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), QGEN: 22.15 (+0.11)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), HOLX: 35.71 (+0.10)
AmSurg, Envision Healthcare Set to Merge by 2016-End
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:47AM CDT
Envision shareholders will own 53% of the combined entity while AmSurg (AMSG) shareholders will have 47%.
AMSG: 80.26 (+0.53), EVHC: 26.24 (+0.24), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56)
Hill-Rom Holdings (HRC) Looks Good: Stock Adds 5.4% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:40AM CDT
Hill-Rom Holdings, Inc. (HRC) saw its shares rise almost 7% in the last trading session.
BAX: 46.85 (+0.36), HRC: 51.23 (+0.19)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), ILMN: 148.99 (+9.35), GHDX: 27.90 (-0.01)
Zacks.com featured highlights: Cimpress, Ubiquiti Networks, Baxter International, Home Depot and Electronic Arts
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Cimpress, Ubiquiti Networks, Baxter International, Home Depot and Electronic Arts
HD: 134.84 (-0.31), UBNT: 39.79 (+0.27), EA: 79.51 (+0.34), BAX: 46.85 (+0.36), CMPR: 97.66 (+1.04)
Data Show Sigma Spectrum Infusion System Users Achieved 97 Percent Drug Library Compliance Rate within the First Month of Implementation(1)
BusinessWire - Thu Jun 16, 7:15AM CDT
Baxter International (NYSE: BAX) is committed to enhancing patient safety during medication delivery, and today highlighted compliance data showing facilities that implemented Sigma Spectrum Infusion Systems achieved an overall average of 97 percent drug library compliance within the first 30 days of implementation.(1) Consistent use of drug libraries is critical to help identify and prevent potentially harmful medication infusion errors. Each year in the United States, there are an estimated 1.2 million preventable harmful medication errors associated with injectable medications.(3)
BAX: 46.85 (+0.36)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), QGEN: 22.15 (+0.11), NUVA: 61.00 (-0.57)
Next Resistance Level for Baxter International (BAX) is $47.00
Comtex SmarTrend(R) - Mon Jul 11, 8:44AM CDT
Shares of Baxter International (NYSE:BAX) have bullishly opened above the pivot of $46.50 today and have reached the first resistance level of $46.82. Investors may be interested in a cross of the next upside pivot targets of $47.00 and $47.50.
BAX: 46.85 (+0.36)
Baxter International: Health Canada Okays AMIA APD System
Zacks Equity Research - Zacks Investment Research - Thu Jun 30, 7:27AM CDT
Baxter International Inc. (BAX) is forging ahead with its expansion plans in Canada with the launch of AMIA Automated Peritoneal Dialysis (APD) System.
BSX: 23.64 (-0.13), ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), NUVA: 61.00 (-0.57)
Baxter Recognized as One of the Most Community-Minded Companies in the United States by Points of Light
BusinessWire - Tue Jun 28, 2:00PM CDT
Baxter International Inc. was recognized for the third consecutive year as one of the most community-minded companies in the nation, as a part of the Civic 50. Civic 50 is an initiative of Points of Light - the world's largest organization dedicated to volunteer service, mobilizes millions of people to take action and change the world. Points of Light sets the standard for corporate civic engagement and creates a roadmap for companies seeking to best use their time, talent, and resources to improve the quality of life in the communities where they do business.
BAX: 46.85 (+0.36)
ResMed : All Eyes on Brightree Buyout , Growth Plans on Track
Zacks Equity Research - Zacks Investment Research - Mon Jun 27, 9:11AM CDT
ResMed's partnership with Brightree will expand its Air solutions platform thus increasing its end-to-end value proposition by boosting its SDB products.
ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), ENZY: 8.54 (-0.08), RMD: 64.02 (-0.26)
Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 8:30AM CDT
Baxter International, Fluor, BlackRock, Legg Mason and Invesco highlighted as Zacks Bull and Bear of the Day
BLK: 357.37 (+9.87), BAX: 46.85 (+0.36), IVZ: 26.86 (+1.04), FLR: 53.19 (+1.15), LM: 31.26 (+1.02)
Genomic Health: Can the Liquid Biopsy Test Boost Margins?
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 7:50AM CDT
Genomic Health (GHDX) recently launched a next-generation sequencing blood-based mutational panel -- Oncotype SEQ Liquid Select.
BSX: 23.64 (-0.13), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), GHDX: 27.90 (-0.01)
FDA Okays Trial for Medtronic's MRI-Guided Epilepsy Device
Zacks Equity Research - Zacks Investment Research - Fri Jun 24, 6:31AM CDT
With surgical procedures gaining ground in the treatment of drug-resistant epilepsy, the FDA go-ahead will expand Medtronic's (MDT) footprint in the billion-dollar neurosurgical market.
ICUI: 115.22 (-0.52), MDT: 88.92 (+0.41), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56)
Bull of the Day: Baxter International (BAX)
Jeremy Mullin - Zacks Investment Research - Fri Jun 24, 6:00AM CDT
Bull of the Day: Baxter International (BAX)
BAX: 46.85 (+0.36)
GNC Gains as Buyout Rumors of Vitamin Shoppe Resurface
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 5:32AM CDT
The Vitamin Shoppe buyout rumor first buzzed in immediately after GNC Holdings Inc.'s (GNC) earnings call in the last quarter.
BSX: 23.64 (-0.13), HLF: 61.87 (+0.89), BAX: 46.85 (+0.36), GNC: 26.34 (+0.59)
Hologic: FDA Okays Procleix Zika Virus Test under IND Study
Zacks Equity Research - Zacks Investment Research - Wed Jun 22, 7:51AM CDT
Hologic's (HOLX) Procleix Zika Virus Test was approved under FDA???s Investigational New Drug (IND) study protocol to detect the presence of Zika virus in donated blood.
ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), HOLX: 35.71 (+0.10)
Stryker (SYK) Hits 52-Week High on Positive FY16 View
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 9:14AM CDT
Share price of Stryker Corp (SYK) rallied to a new 52-week high of $116.99 on Jun 20.
MASI: 52.52 (+0.07), BAX: 46.85 (+0.36), CRY: 12.20 (+0.01), SYK: 122.82 (+0.17)
Qiagen's Q1 Results Hit by Currency, Competition Rife
Zacks Equity Research - Zacks Investment Research - Tue Jun 21, 8:32AM CDT
Qiagen (QGEN) is facing increasing competition from firms that provide pre-analytical solutions and other products.
BSX: 23.64 (-0.13), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), QGEN: 22.15 (+0.11)
Hologic's Zika Virus Test Gets FDA Nod for Emergency Use
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 7:58AM CDT
Hologic (HOLX) will run the Aptima Zika virus test on its market leading Panther platform, which substantially reduces hands-on time for laboratories and the potential for manual errors.
ICUI: 115.22 (-0.52), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), HOLX: 35.71 (+0.10)
AmSurg, Envision Healthcare Set to Merge by 2016-End
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 8:47AM CDT
Envision shareholders will own 53% of the combined entity while AmSurg (AMSG) shareholders will have 47%.
AMSG: 80.26 (+0.53), EVHC: 26.24 (+0.24), BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56)
Hill-Rom Holdings (HRC) Looks Good: Stock Adds 5.4% in Session
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:40AM CDT
Hill-Rom Holdings, Inc. (HRC) saw its shares rise almost 7% in the last trading session.
BAX: 46.85 (+0.36), HRC: 51.23 (+0.19)
Genomic Health Brings Liquid Biopsy Test for Stage IV Cancer
Zacks Equity Research - Zacks Investment Research - Fri Jun 17, 7:13AM CDT
Genomic's (GHDX) Oncotype SEQ facilitates personalized treatment of patients suffering from stage four solid tumor cancer.
BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), ILMN: 148.99 (+9.35), GHDX: 27.90 (-0.01)
Zacks.com featured highlights: Cimpress, Ubiquiti Networks, Baxter International, Home Depot and Electronic Arts
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:30AM CDT
Zacks.com featured highlights: Cimpress, Ubiquiti Networks, Baxter International, Home Depot and Electronic Arts
HD: 134.84 (-0.31), UBNT: 39.79 (+0.27), EA: 79.51 (+0.34), BAX: 46.85 (+0.36), CMPR: 97.66 (+1.04)
Data Show Sigma Spectrum Infusion System Users Achieved 97 Percent Drug Library Compliance Rate within the First Month of Implementation(1)
BusinessWire - Thu Jun 16, 7:15AM CDT
Baxter International (NYSE: BAX) is committed to enhancing patient safety during medication delivery, and today highlighted compliance data showing facilities that implemented Sigma Spectrum Infusion Systems achieved an overall average of 97 percent drug library compliance within the first 30 days of implementation.(1) Consistent use of drug libraries is critical to help identify and prevent potentially harmful medication infusion errors. Each year in the United States, there are an estimated 1.2 million preventable harmful medication errors associated with injectable medications.(3)
BAX: 46.85 (+0.36)
Qiagen???s QIAsure Test to Determine Cervical Cancer Risks
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 7:33AM CDT
Qiagen's (QGEN) QIAsure accurately stratifies cervical cancer risk, which offers highly sensitive and specific results for patients and clinicians.
BAX: 46.85 (+0.36), LMAT: 14.20 (+0.56), QGEN: 22.15 (+0.11), NUVA: 61.00 (-0.57)
